E3 PreliminaryPreliminaryPEM ?Case-ControlPeer-reviewedMachine draft
N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports.
Wiebe, E · Canadian family physician Medecin de famille canadien · 1996
Quick Summary
This study looked at two individual ME/CFS patients to see which treatments might help them personally. One patient tried high-dose vitamin B12 injections but they didn't help. Another patient tried a medication called nimodipine and found it worked very well for them. The doctors used a special testing method called N of 1 trials, where treatments are tested in one person at a time to see what actually helps that specific individual.
Why It Matters
This study highlights the potential value of personalized treatment testing in ME/CFS, where heterogeneity means patients respond differently to interventions. It suggests that N of 1 trial methodology could be a useful clinical tool for physicians managing individual ME/CFS patients who need to identify which specific treatments work for them.
Observed Findings
- High-dose vitamin B12 injections showed no clinical improvement in Patient 1
- Nimodipine produced very effective symptom improvement in Patient 2
- N of 1 trial methodology was feasible for individualizing ME/CFS treatment decisions
Inferred Conclusions
- N of 1 trials may be a useful approach for identifying effective treatments in individual ME/CFS patients
- Treatment response to the same intervention varies considerably between patients with ME/CFS
- Personalized testing may be necessary to determine which patients benefit from specific therapies
Remaining Questions
- What proportion of ME/CFS patients would respond to nimodipine or vitamin B12?
- What are the mechanisms of action in responders versus non-responders?
- How can N of 1 trials be systematized for broader clinical use in ME/CFS management?
- Would results be reproducible with longer follow-up or repeated testing?
What This Study Does Not Prove
This study does NOT prove that vitamin B12 is ineffective for all ME/CFS patients or that nimodipine is a general cure—these were only two individual cases. The findings cannot be applied broadly to the ME/CFS population, and single-case responses do not establish causation or provide evidence of efficacy beyond the individuals studied. Placebo effects and natural symptom fluctuation are not controlled for.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- PMID
- 8939323
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026